195 related articles for article (PubMed ID: 11145946)
1. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.
Collet JP; Montalescot G; Lesty C; Soria J; Mishal Z; Thomas D; Soria C
Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):142-8. PubMed ID: 11145946
[TBL] [Abstract][Full Text] [Related]
2. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots.
Collet JP; Montalescot G; Lesty C; Weisel JW
Circ Res; 2002 Mar; 90(4):428-34. PubMed ID: 11884372
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
[TBL] [Abstract][Full Text] [Related]
4. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention.
Collet JP; Montalescot G; Lesty C; Mishal Z; Soria J; Choussat R; Drobinski G; Soria C; Pinton P; Barragan P; Thomas D
Circulation; 2001 May; 103(19):2328-31. PubMed ID: 11352878
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
6. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
7. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography.
Katori N; Tanaka KA; Szlam F; Levy JH
Anesth Analg; 2005 Jun; 100(6):1781-1785. PubMed ID: 15920213
[TBL] [Abstract][Full Text] [Related]
8. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
9. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
[TBL] [Abstract][Full Text] [Related]
10. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
11. Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
James SK; Siegbahn A; Armstrong P; Barnathan E; Califf R; Simoons ML; Wallentin L
Am Heart J; 2004 Feb; 147(2):267-74. PubMed ID: 14760324
[TBL] [Abstract][Full Text] [Related]
12. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Braaten JV; Jerome WG; Hantgan RR
Blood; 1994 Feb; 83(4):982-93. PubMed ID: 8111066
[TBL] [Abstract][Full Text] [Related]
13. Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor.
Altman R; Scazziota A; Santoro S; Gonzalez C
Clin Appl Thromb Hemost; 2005 Jul; 11(3):271-7. PubMed ID: 16015412
[TBL] [Abstract][Full Text] [Related]
14. The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood.
Carrieri C; Galasso R; Semeraro F; Ammollo CT; Semeraro N; Colucci M
J Thromb Haemost; 2011 Jan; 9(1):154-62. PubMed ID: 20961395
[TBL] [Abstract][Full Text] [Related]
15. Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets.
Ilveskero S; Lassila R
J Thromb Haemost; 2003 Apr; 1(4):805-13. PubMed ID: 12871419
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
[TBL] [Abstract][Full Text] [Related]
17. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography.
Khurana S; Mattson JC; Westley S; O'Neill WW; Timmis GC; Safian RD
J Lab Clin Med; 1997 Oct; 130(4):401-11. PubMed ID: 9358079
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus.
Coiffic A; Cazes E; Janvier G; Forestier F; Lanza F; Nurden A; Nurden P
Thromb Res; 1999 Jul; 95(2):83-91. PubMed ID: 10418797
[TBL] [Abstract][Full Text] [Related]
19. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
[TBL] [Abstract][Full Text] [Related]
20. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
Schneider DJ; Baumann PQ; Holmes MB; Taatjes DJ; Sobel BE
Thromb Haemost; 2001 Feb; 85(2):309-13. PubMed ID: 11246553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
